NeuBase Therapeutics Inc

NBSE NASDAQ
4.750
-0.195
-3.94%
Closed 16:00 08/16 EDT
Open
4.940
Prev Close
4.945
High
5.08
Low
4.650
Volume
54.29K
Avg Vol (3M)
164.36K
52 Week High
6.28
52 Week Low
1.582
% Turnover
0.32%
Market Cap
81.08M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers NeuBase Therapeutics Inc NBSE stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

NeuBase Therapeutics, Inc., formerly Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company's development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company's animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin.
MORE >

Recently

Name
Price
%Change